Drug resistance associated with antiangiogenesis therapy

Hans Petter Eikesdal; Raghu Kalluri

doi:10.1016/j.semcancer.2009.05.006

Drug resistance associated with antiangiogenesis therapy

Hans Petter Eikesdal, Raghu Kalluri

Research output: Contribution to journal › Review article › peer-review

53 Scopus citations

Abstract

Neovascularization is one of the hallmarks associated with tumor growth. In the recent years, a number of angiogenesis inhibitors have been approved for clinical use in cancer patients. However, the efficacy of antiangiogenic therapy is in most cases short-lasting, with likely drug resistance developing within a few months. It is becoming clear also that there are a subset of malignant tumors that are inherently resistant to angiogenesis inhibition. The knowledge regarding resistance mechanisms towards angiogenesis inhibitors is still evolving and here we propose some theories and in some cases provide experimental evidence.

Original language	English (US)
Pages (from-to)	310-317
Number of pages	8
Journal	Seminars in cancer biology
Volume	19
Issue number	5
DOIs	https://doi.org/10.1016/j.semcancer.2009.05.006
State	Published - Oct 2009
Externally published	Yes

Keywords

Angiogenesis
Antiangiogenic therapy
Cancer
Drug resistance mechanisms

ASJC Scopus subject areas

Cancer Research

Access to Document

10.1016/j.semcancer.2009.05.006

Cite this

@article{ceb992f4474f40e0a2ecd1573bbb4fe3,

title = "Drug resistance associated with antiangiogenesis therapy",

abstract = "Neovascularization is one of the hallmarks associated with tumor growth. In the recent years, a number of angiogenesis inhibitors have been approved for clinical use in cancer patients. However, the efficacy of antiangiogenic therapy is in most cases short-lasting, with likely drug resistance developing within a few months. It is becoming clear also that there are a subset of malignant tumors that are inherently resistant to angiogenesis inhibition. The knowledge regarding resistance mechanisms towards angiogenesis inhibitors is still evolving and here we propose some theories and in some cases provide experimental evidence.",

keywords = "Angiogenesis, Antiangiogenic therapy, Cancer, Drug resistance mechanisms",

author = "Eikesdal, {Hans Petter} and Raghu Kalluri",

note = "Funding Information: This work was primarily supported by National Institutes of Health Grant CA12550 and partially by National Institutes of Health Grants DK55001, DK61688, AA13913, and DK62987 and funds from the Department of Medicine for the Division of Matrix Biology at Beth Israel Deaconess Medical Center. This work was also supported by the Champalimaud Foundation. HPE was supported by grants from the University of Bergen, Helse Vest, the Eckbo Legacy and the Fulbright Association, Norway. We thank Dr. Elisabeth Zeisberg for providing us with the Tie2-LacZ picture.",

year = "2009",

month = oct,

doi = "10.1016/j.semcancer.2009.05.006",

language = "English (US)",

volume = "19",

pages = "310--317",

journal = "Seminars in cancer biology",

issn = "1044-579X",

publisher = "Academic Press Inc.",

number = "5",

}

TY - JOUR

T1 - Drug resistance associated with antiangiogenesis therapy

AU - Eikesdal, Hans Petter

AU - Kalluri, Raghu

N1 - Funding Information: This work was primarily supported by National Institutes of Health Grant CA12550 and partially by National Institutes of Health Grants DK55001, DK61688, AA13913, and DK62987 and funds from the Department of Medicine for the Division of Matrix Biology at Beth Israel Deaconess Medical Center. This work was also supported by the Champalimaud Foundation. HPE was supported by grants from the University of Bergen, Helse Vest, the Eckbo Legacy and the Fulbright Association, Norway. We thank Dr. Elisabeth Zeisberg for providing us with the Tie2-LacZ picture.

PY - 2009/10

Y1 - 2009/10

N2 - Neovascularization is one of the hallmarks associated with tumor growth. In the recent years, a number of angiogenesis inhibitors have been approved for clinical use in cancer patients. However, the efficacy of antiangiogenic therapy is in most cases short-lasting, with likely drug resistance developing within a few months. It is becoming clear also that there are a subset of malignant tumors that are inherently resistant to angiogenesis inhibition. The knowledge regarding resistance mechanisms towards angiogenesis inhibitors is still evolving and here we propose some theories and in some cases provide experimental evidence.

AB - Neovascularization is one of the hallmarks associated with tumor growth. In the recent years, a number of angiogenesis inhibitors have been approved for clinical use in cancer patients. However, the efficacy of antiangiogenic therapy is in most cases short-lasting, with likely drug resistance developing within a few months. It is becoming clear also that there are a subset of malignant tumors that are inherently resistant to angiogenesis inhibition. The knowledge regarding resistance mechanisms towards angiogenesis inhibitors is still evolving and here we propose some theories and in some cases provide experimental evidence.

KW - Angiogenesis

KW - Antiangiogenic therapy

KW - Cancer

KW - Drug resistance mechanisms

UR - http://www.scopus.com/inward/record.url?scp=70549102293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70549102293&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2009.05.006

DO - 10.1016/j.semcancer.2009.05.006

M3 - Review article

C2 - 19524042

AN - SCOPUS:70549102293

SN - 1044-579X

VL - 19

SP - 310

EP - 317

JO - Seminars in cancer biology

JF - Seminars in cancer biology

IS - 5

ER -

Drug resistance associated with antiangiogenesis therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this